Skip to content

Perflexane

Contrast Agent for Ultrasound Imaging

Also known as: perfluorohexane, tetradecafluorohexane

OfmFDA approved

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Perflexane is an ofm drug in the Contrast Agent for Ultrasound Imaging class catalogued in DrugCentral. It was first approved by the FDA in 2002. Its mechanism of action is classified as Ultrasound Contrast Activity.

  • Approval status: ofm (first approved 2002 by the FDA).
  • Drug class: Contrast Agent for Ultrasound Imaging.
  • Mechanism of action: Ultrasound Contrast Activity.
  • Molecular formula: C6F14; molecular weight 338.04 g/mol.

Mechanism & targets

Mechanism of action (MoA)Ultrasound Contrast Activity
Established pharmacologic classContrast Agent for Ultrasound Imaging

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2002-05-31FDA——

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Perflexane is on its molecule page.

Molecular formulaC6F14
Molecular weight338.04 g/mol
CAS number—
InChIKeyZJIJAJXFLBMLCK-UHFFFAOYSA-N
PubChem CID9639
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Perflexane work?

Perflexane is classified as Ultrasound Contrast Activity.

When was Perflexane first approved?

Perflexane was first approved by the FDA in 2002.

What drug class does Perflexane belong to?

Perflexane is in the Contrast Agent for Ultrasound Imaging class.

What is the chemical formula of Perflexane?

Perflexane has the molecular formula C6F14 and a molecular weight of 338.04 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval2002-05-31
AgencyFDA
Targets0
Indications0
FormulaC6F14
DrugCentral ID3429
Interactive profile